PURPOSE: To assess the efficacy and safety of primary systemic treatment with doxorubicin and paclitaxel in patients with early breast cancer. PATIENTS AND METHODS: Forty patients with newly diagnosed, histologically confirmed breast cancer (T2, N0-1, M0) received primary chemotherapy with doxorubicin (60 mg/m2) and paclitaxel (200 mg/m2) in 3-week intervals for up to four courses. RESULTS: A total of 151 cycles were administered. The clinical response rate as assessed by sonographic measurement was 70%, and complete remissions of the primary tumor occurred in two patients. Eight patients (20%) had histologically confirmed complete responses. Predominant toxicity was myelosuppression with grade 3/4 neutropenia in 70% of patients. Non-hematological toxicity was generally moderate. Grade 4 non-hematological toxicities were not observed and grade 3 toxicity was reported with alopecia (98%) and stomatitis (10%). CONCLUSIONS: The combination of doxorubicin and paclitaxel is safe and highly active in patients with early breast cancer. The evaluated schedule is suitable for phase III studies.
PURPOSE: To assess the efficacy and safety of primary systemic treatment with doxorubicin and paclitaxel in patients with early breast cancer. PATIENTS AND METHODS: Forty patients with newly diagnosed, histologically confirmed breast cancer (T2, N0-1, M0) received primary chemotherapy with doxorubicin (60 mg/m2) and paclitaxel (200 mg/m2) in 3-week intervals for up to four courses. RESULTS: A total of 151 cycles were administered. The clinical response rate as assessed by sonographic measurement was 70%, and complete remissions of the primary tumor occurred in two patients. Eight patients (20%) had histologically confirmed complete responses. Predominant toxicity was myelosuppression with grade 3/4 neutropenia in 70% of patients. Non-hematological toxicity was generally moderate. Grade 4 non-hematological toxicities were not observed and grade 3 toxicity was reported with alopecia (98%) and stomatitis (10%). CONCLUSIONS: The combination of doxorubicin and paclitaxel is safe and highly active in patients with early breast cancer. The evaluated schedule is suitable for phase III studies.
Authors: P Broët; S M Scholl; A de la Rochefordière; A Fourquet; T Moreau; Y De Rycke; B Asselain; P Pouillart Journal: Breast Cancer Res Treat Date: 1999-11 Impact factor: 4.872
Authors: A Moliterni; E Tarenzi; G Capri; M Terenziani; A Bertuzzi; G Grasselli; R Agresti; P Piotti; M Greco; B Salvadori; S Pilotti; F Lombardi; P Valagussa; G Bonadonna; L Gianni Journal: Semin Oncol Date: 1997-10 Impact factor: 4.929
Authors: S M Scholl; A Fourquet; B Asselain; J Y Pierga; J R Vilcoq; J C Durand; T Dorval; T Palangié; M Jouve; P Beuzeboc Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: A U Buzdar; S E Singletary; R L Theriault; D J Booser; V Valero; N Ibrahim; T L Smith; L Asmar; D Frye; N Manuel; S W Kau; M McNeese; E Strom; K Hunt; F Ames; G N Hortobagyi Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: G von Minckwitz; S D Costa; W Eiermann; J U Blohmer; A H Tulusan; C Jackisch; M Kaufmann Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: L Mauriac; G MacGrogan; A Avril; M Durand; A Floquet; M Debled; J M Dilhuydy; F Bonichon Journal: Ann Oncol Date: 1999-01 Impact factor: 32.976
Authors: Ian C Smith; Steven D Heys; Andrew W Hutcheon; Iain D Miller; Simon Payne; Fiona J Gilbert; Antoinne K Ah-See; Oleg Eremin; Leslie G Walker; Tarun K Sarkar; S Peter Eggleton; Keith N Ogston Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: V F Semiglazov; E E Topuzov; J L Bavli; V M Moiseyenko; O A Ivanova; I K Seleznev; A A Orlov; N Y Barash; O M Golubeva; O F Chepic Journal: Ann Oncol Date: 1994-09 Impact factor: 32.976